Ultrasound-guided supraclavicular cannulation of the brachiocephalic vein may reduce central line-associated bloodstream infection in preterm infants.

The objective of this study was to assess the risk of central line-associated bloodstream infection (CLABSI) of ultrasound (US)-guided cannulation of the brachiocephalic vein (BCV) compared to standard epicutaneous cava catheters (ECCs) in preterm infants. This was a retrospective cohort study in preterm infants with a birth weight of less than 1500 g. Each BCV catheter was matched 1:3 with ECCs according to sex, birth weight, and year of insertion. The main outcome was the CLABSI density rate per 1000 days. Secondary outcomes included CLABSI episodes, CLABSI episodes per infant, and CLABSI/death. A multivariate Cox regression analysis was performed to assess whether the type of catheter (ECC vs. BCV) was associated with CLABSI risk. Ninety-six catheters (21 BCVs and 75 ECCs) in 79 infants were included (993 catheter days). BCV catheters were associated with a reduced CLABSI density rate compared to ECCs (3.05/1000 days vs 21.1/1000 days; p < 0.001). ECCs were associated with increased CLABSI risk compared to BCV catheters in multivariate analysis (hazard ratio 36; (95% CI, 2.5-511); p = 0.008).
Conclusion: US-guided supraclavicular cannulation of the BCV was associated with a reduced risk of CLABSI compared to ECCs. This finding deserves further multicenter research. What is Known: • An epicutaneous-cava catheter (ECC) is commonly used in preterm infants for routine care (eg. delivery of nutrition and antibiotics) but this device may not suffice in infants who need high-intensity care (multiple drugs, hemodynamic monitoring, fluid resuscitation etc.). • Ultrasound-guided brachiocephalic vein (BCV) catheterization has shown a high success rate and few immediate complications in neonates and small infants but it has never been compared to standard ECCs. What is New: • When the operator in properly trained, US guided cannulation of the BCV in preterm infants is feasible, safe and may reduce the risk of CLABSI compared to standard ECCs. • This fact may expand the use of BCV catheters in selected high-risk preterm infants who need a large bore venous access.

Introduction

Insertion of a central venous catheter (CVC) is commonly used in preterm infants admitted to the neonatal intensive care unit (NICU). The two most common vein-access techniques in this population are umbilical vein catheters (UVCs) during the first days of life and peripherally inserted central catheters (ECCs) thereafter [1].

Occasionally, for the sickest preterm infants, large-bore percutaneous CVC may be needed for fluid resuscitation, for drug administration, for hemodynamic monitoring, or after peripheral vein exhaustion [2, 3]. A relatively new technique consisting of US-guided cannulation of the brachiocephalic vein (BCV) from a supraclavicular approach has been associated with a high success rate and few complications in infants and neonates [4, 5]. However, no study to date has assessed the potential advantages of this approach in terms of central line–associated bloodstream infection (CLABSI) in neonates. In our unit, we have implemented US-guided insertion of large-bore percutaneous CVCs through the BCV in selected sick neonates and small infants, with good results [6]. In this study, we tested the hypothesis that US-guided BCV cannulation has a lower risk of CLABSI than standard ECCs in preterm infants.

Methods

Design and setting

This is a retrospective cohort study of preterm infants admitted to a tertiary level-3B NICU between January 1, 2016, and December 31, 2019.

Participants

Very-low-birth-weight infants (< 1500 g) under 34 weeks of gestational age in whom US-guided BCV cannulation or ECC insertion was performed were eligible. BCV and ECC procedures were matched 1:3 according to the patient’s birth weight, sex, and year of insertion. Infants with CVCs in place for less than 6 hours, who died within the first 48 hours of life or for whom data records were incomplete, were excluded from the analysis. Infants were followed until discharge from the Neonatal Unit.

CVC indications, insertion technique, and maintenance policy

In this study, the exposure variable was the type of CVC inserted (exposed: BCV; unexposed: ECC). In our unit, preterm infants below 33 weeks of gestation receive a UVC at admission to the NICU as a general rule. In general, UVCs are withdrawn electively as soon as possible after the 4th day of life (DOL) and always before the 10th DOL and substituted by an ECC or a peripheral cannula depending on the patient’s clinical condition and the ongoing need for a CVC. ECCs are inserted through forearm veins without US guidance under sterile conditions and advanced to the distal third portion of the superior vena cava (SVC). CVC tip position is checked by a chest X-ray. A noncentral catheter tip position at the intrathoracic subclavian or brachiocephalic vein is sometimes accepted. During the study period, bilumen 2 French polyurethane ECC lines (Nutriline Twinflow®, Vygon; Aachen, Germany) were used. Non-pharmacological sedation methods (contention) and 24% sucrose solution are routinely used. Only neonatal nurses are qualified to place ECCs. Neonatal nurses work full time in the neonatal unit. They must have a 2-year experience in pediatric nursing (including a 6-month rotation in the neonatal unit) and a supervised training by senior staff in ECC placement before they are qualified to perform the procedure autonomously.

Selected infants are considered candidates for percutaneous insertion of a large-bore CVC. Indications include severe hemodynamic instability (e.g., pulmonary hypertension, septic shock), high-risk surgery (e.g., necrotizing enterocolitis (NEC) surgery or patent ductus arteriosus (PDA) ligation), the need for multiple drug infusions, or exhausted peripheral veins. From 2014, we implemented in-plane US-guided supraclavicular BCV cannulation as the technique of choice for critically infants and neonates under 5 kg. In this study, all procedures were performed by a pediatrician with 10 years of experience in US-guided CVC placement in children (including more than 150 procedures using the supraclavicular BCV approach). A portable US machine (Sonosite Turbo, Fujifilm Japan) equipped with a linear 6–13-MHz transducer (L25x linear probe) was used. Prior to the procedure, the left and right BCV diameters were assessed. The optimal catheter size was selected by keeping a catheter:vein ratio of ≤ 1:3 to prevent blood flow obstruction and thrombosis [7, 8]. Double-lumen 3- and 4-French short (5–6 cm), noncoated catheters were used in all instances (Multicath 2®, Vygon; Aachen, Germany and Standard Unimpregnated CVC, Cookmedical; Bloomington, IN, USA) depending on the size of the vein. All procedures were performed using the conventional Seldinger technique under sterile conditions and pharmacological sedation. Nonintubated preterms were sedated with midazolam (0.05–0.1 mg/kg) and ketamine (0.5–1 mg/kg) while fentanyl (1 mcg/kg) was used in infants under invasive mechanical ventilation. Mepivacaine 2% was used for local anesthesia of the skin (maximal dose 5 mg). The cannulation side that provided a better long-axis view of the BCV was selected, and the patient was positioned with the neck extended and rotated 45° opposite to that side. For patients under mechanical ventilation, the ventilator settings were not manipulated during cannulation. The linear transducer was positioned in the supraclavicular area to obtain a long-axis view of the BCV and subclavian vein. The subclavian artery and the underlying lung pleura were identified before puncture. A 22-gauge echogenic introducer needle attached to a syringe was used to puncture the vein. The needle was inserted in plane from the lateral aspect of the transducer and directed under real-time visualization to the BCV. Blood was aspirated to confirm intravascular positioning, and a straight soft-tipped 0.018-in. guidewire was advanced into the vessel and checked by US visualization. The CVC tip was navigated and adequacy of tip position was assessed by real-time cardiac and vascular US using a predefined protocol [9]. A noncentral catheter tip position was not allowed. The procedure was completed as usual and the catheter was fixed using 5–0 non-absorbable surgical suture.

The same maintenance policy is invoked for all CVCs. Catheters are always manipulated under sterile conditions, avoiding (if possible) 3-way stop-lockers. A unique port is reserved for parenteral nutrition. Low-dose heparin (0.5 U/kg/h) infusion is used to maintain catheter patency [10]. Transparent dressings are used and changed every 7 days or when blood is present or the dressing is disrupted. The catheter insertion site is assessed daily for signs of infection such as redness, swelling, or purulent discharge. When CLABSI is suspected, peripheral blood cultures with or without paired central line blood cultures are obtained, and empiric antibiotics (vancomycin plus amikacin) are started. The catheter is withdrawn if CLABSI is confirmed or if the infant deteriorates, except in cases of coagulase-negative Staphylococcus (CoNS), in which the CVC is initially kept in place under close monitoring. Surveillance blood or catheter tip cultures are not performed for asymptomatic patients.

Measurements and outcomes

Perinatal data, clinical characteristics, and catheter-related outcomes were prospectively recorded according to a nationwide registry (SEN1500 network) and the European healthcare-associated infections surveillance system (NEO-KISS network) [11, 12]. Periprocedural data (first attempt and overall success, number of puncture attempts, immediate complications, etc.) were prospectively recorded as a part of an ongoing local registry of percutaneous CVCs.

The main outcome of this study was the CLABSI rate per 1000 days of catheter use. Secondary outcomes included CLABSI episodes per infant (no. of CLABSI episodes/no. of infants), CLABSI episodes per catheter (no. of CLABSI episodes/no. of catheters) and combined CLABSI per infant or death. CLABSI was defined as the presence of clinical symptoms of sepsis (at least two of the following: fever, hypothermia, apnea, bradycardia, respiratory distress, poor peripheral perfusion, or hypotension) with elevated acute-phase reactants (C-reactive protein ≥ 10 mg/dl and/or procalcitonin > 3 ng/ml beyond the 72 h of life) [13] and a positive blood or catheter tip culture in the first 48 h after catheter insertion until 48 h after catheter withdrawal. In the case of CoNS, ≥ 2 positive blood cultures drawn at different time points were necessary to diagnose CLABSI according to the current CDC/NHSN surveillance definition [14]. With the aim of being pragmatic, if ≥ 2 peripheral blood cultures could not be obtained, CoNS-CLABSI was considered proven if blood and catheter tip cultures were positive for a CoNS with an identical antibiogram.

Statistical analysis

Categorical variables are summarized as numbers (percentages), and continuous variables are summarized as medians (interquartile ranges) and means (standard deviations). The chi-square test was employed for comparisons of categorical variables; nonparametric tests (the Mann-Whitney U test) were used for comparisons of continuous variables. The occurrence of CLABSI was estimated with the Kaplan-Meier product-limit estimator and log-rank test. A multivariate Cox regression analysis was performed to assess whether CVC type (ECC vs BCV) is an independent risk factor for CLABSI. Potential risk factors for CLABSI with p < 0.1 as the entry criterion were selected by the step-forward method for the multivariate model, with the aim of controlling confounders. Assuming that infants have the same chance to receive either CVC type (BCV or ECC) and a matched design with an exposed:unexposed ratio of 1:3, a sample size of 20 BCV (and 60 ECCs) will provide a power of 0.8 (alpha error 0.05) to detect a 3-fold decrease in the CLABSI density rate. With a planned insertion of 5 BCV catheters/year, we chose a time window of 4 years to extract data from our cohort to convey with our sample size calculation. A p value < 0.05 was considered statistically significant. The SPSS (IBM Corp., Arkmonk, N.Y., USA) statistical package version 22 was used.

Ethical aspects

The study protocol was reviewed and approved by the local IRB. Parents gave informed consent for data entry into the SEN1500 and NEO-KISS network records. Given the retrospective nature of our study, the IRB waived the need for informed consent for the present analysis.

Results

Ninety-six CVCs (21 BCV catheters and 75 ECCs) in 79 infants were included (Table 1). Another 38 VLBW infants were initially assessed for eligibility during the study period but excluded for several reasons (Fig. 1). In one infant, BCV cannulation failed, and an internal jugular vein catheter was inserted; he was also prospectively excluded. All patients received a UVC for a median of 8 days [6-8] before ECC or BCV insertion. Preterm infants in whom US-guided BCV catheters were inserted had a lower gestational age and suffered from more morbidities (mechanical ventilation days, inotropic use, blood transfusion, hemodynamically significant PDA, NEC) than infants with ECCs.

Table 1

Clinical characteristics of the study groups

Clinical characteristics	BCV (n = 21)	ECC (n = 58)	p
Sex (female)	8 (38.1)	19 (32.7)	0.659
Gestational age (weeks)	27 (26 + 1–27 + 1)	27 + 6 (26 + 6–29 + 4)	0.002
Birth weight (grams)	980 (815–1090)	990 (786–1172)	0.731
Cesarean delivery	15 (71.4)	38 (65.5)	0.621
Twin pregnancy	3 (14.3)	14 (24.1)	0.341
Maternal chorioamnionitis	4 (19)	7 (12.1)	0.429
Antenatal steroids	18 (81.8)	55 (94.5)	0.177
Apgar 5 min	8 (6–8)	8 (7–9)	0.021
CRIB score 12 h	4 (2.5–6)	2.5 (1–6)	0.392
Perinatal risk factors of infection	15 (71.4)	45 (77.6)	0.484
RDS (surfactant replacement)	15 (71.4)	29 (50)	0.090
Invasive mechanical ventilation (days)	6 (3.5–10)	6 (3.5–10)	0.015
Inotropics/vasopressors	18 (85.7)	33 (56.8)	0.027
Blood transfusion	18 (85.7)	35 (60.3)	0.034
Retinopathy	3 (14%)	5 (8.6)	0.476
Grade III/IV IVH	2 (9.5)	6 (10.3)	0.915
Hemodynamically significant PDA	14 (66.6)	26 (44.8)	0.086
PDA surgery	5 (23.8)	0 (0)	0.005
Necrotizing enterocolitis	7 (33%)	7 (12.1)	0.029
Bronchopulmonary dysplasia*	12 (57.1)	29 (50)	0.575
Death	2 (9.5)	5 (8.6)	0.767
Cause of death:
-Adequacy of life support	1	3
-Septic shock/NEC	0	2	–
-Respiratory failure	1	0

Abbreviations: CRIB clinical risk index for babies; IVH intraventricular hemorrhage; NEC necrotizing enterocolitis; PDA patent ductus arteriosus; RDS respiratory distress syndrome. *Refers to oxygen and/or ventilator dependency at 36 weeks of postmenstrual age (moderate-severe BPD)

Fig. 1

Flow chart of the study. Abbreviations: BCV, brachiocephalic vein; ECC, peripherally inserted central catheter

The CVC-related outcomes are summarized in Table 2. Compared to ECC insertion, the first-attempt success rate of US-guided BCV cannulation was higher (80.9% vs 42.6%; p < 0.001) (Fig. 2), and the number of punctured veins ((1 [1] vs 2 [1-3]; p = 0.006) and puncture attempts (1 [1] vs 2 [1-3]; p < 0.001) were lower. Accidental arterial punctures and/or pneumothorax were not observed. BCV catheters were inserted later in postnatal life than were ECCs, but the infant’s weight at the time of insertion was similar. Indications for CVCs differed between the study groups: ECCs were used mostly for routine care (maintenance fluids, antibiotics, and parenteral nutrition), whereas BCVs were inserted in cases of high-risk surgery (laparotomy for NEC in 6 infants and gastric volvulus in one infant), hemodynamic instability requiring inotropics and invasive monitoring (PDA postligation syndrome in 4 infants and septic shock in 2 infants), and vein exhaustion (6 infants). Most BCVs were electively withdrawn after completion of treatment; CLABSI and catheter dysfunction were frequent reasons for nonelective removal of ECCs. The indwelling time of BCV catheters was significantly longer than that of PICCs [15 (13–18) days vs. 8 (6–11) days; p < 0.001).

Table 2

Central venous catheter characteristics and outcomes

Characteristics	BCV (n = 21)	ECC (n = 75)	p
CVCs per infant	1 (1–1)	2 (1–4)	0.044
DOL at insertion	12 (9.5–15)	8 (4–10)†	0.001
Weight at insertion	990 (885–1058)	980 (760–1185)	0.940
Number of punctures	1 (1–3)	2 (1–5)	< 0.001
Number of punctures veins	1 (1–1)	2 (1–3)	0.006
CVC indication
-Routine care	1 (4.7)	66 (88)
-Surgery	7 (33.3)	1 (1.3)	< 0.001
-No other access	6 (38.6)	1 (1.3)
-Shock/inotropics	7 (33.3)	2 (2.7)
-Other reasons	0 (0)	5 (6.6)
CVC withdrawal			0.086
-End of treatment	20 (95.3)	50 (66.6)
-Elective change	0 (0)	4 (5.3)
-CLABSI	1 (4.7)	11 (14.7)
-CVC dysfunction	0 (0)	9 (12)
AB days per catheter	14 (12–16)	5 (2–8)	< 0.001
PN days per catheter	13 (8–18)	6 (3–9)	< 0.001
CVC days	15 (13–18)	8 (6–11)	< 0.001
Outcomes	BCV (n = 21)	PICC (n = 75)
CLABSI density rate	3.05/1000	21.1/1000	< 0.001
CLABSI per infant	1 (4.7)	12 (20.7)	0.089
CLABSI episodes	1 (4.7)	14 (18.6)	0.121
CLABSI/death	3 (14.2)	17 (29.3)	0.202
CLABSI pathogen			–
-CNS	0	10
-Staphylococcus aureus	0	1
-Enterococcus	0	1
-Klebsiella	1	1
-Serratia	0	1

Abbreviations: AB parenteral antibiotics; CVC central venous catheter; CLABSI catheter-related blood stream infection; CNS coagulase-negative staphylococcus; DOL day of life; GA gestational age; PN parenteral nutrition days. p values for the U Mann-Whitney test are shown. Data are summarized as median (IQR) except CVC per infant, number of veins punctured, and number of punctures that are summarized as median (range)

Fig. 2

Successful CVC placement at first puncture attempt. Abbreviations: BCV, brachiocephalic vein; ECC, epicutaneous cava catheter. Y-axis indicates percentage with 95% confidence interval error bars

The CLABSI density rate was significantly lower for BCV catheters than ECCs (3.05/1000 CVC days vs. 21.1/1000 CVC days; p < 0.001). One of 21 infants (4.7%) had one CLABSI episode with a BCV catheter, and 12 of 58 infants (20.7%) had 14 episodes of CLABSI with ECCs (p = 0.089). CLABSI episodes per catheter [1/21 (4.7%) vs 14/75 (18.6%), p = 0.121] and CLABSI per infant or death (3/21 (14.25) vs. 17/58 (29.3%); p = 0.202) were not different between the groups. Survival curves using the Kaplan-Meier method with the log-rank test are shown in Fig. 3. CVC type (ECC vs BCV) was associated with increased CLABSI risk in Cox regression analysis after adjustment for weight at insertion time, respiratory distress syndrome, number of CVC placement attempts, and days of antibiotic therapy during CVC dwell time (hazard ratio 36; 95% CI, 2.5–511; p = 0.008) (Table 3).

Fig. 3

Kaplan-Meier curve. Abbreviations: BCV, brachiocephalic vein; ECC, epicutaneous cava catheter

Table 3

Cox regression analysis for the occurrence of CLABSI

Univariate analysis			Multivariate analysis
Dependent variable: CLABSI	Hazard ratio (CI 95%)	p	Dependent variable: CLABSI	Hazard ratio (CI 95%)	p
ECC (vs BCV)	14.2 (1.8–117)	0.013	ECC (vs BCV)	36 (2.5–511)	0.008
CVC placement attempts	1.6 (1.1–2.3)	0.004	CVC placement attempts	1.8 (1.2–2.7)	0.004
RDS (surfactant)	4.6 (1.03–20.8)	0.045	RDS (surfactant)	11.1 (1.2–101)	0.033
Antibiotic days during CVC	0.87 (0.776–0.97)	0.017
Weight at insertion (grams)	0.998 (0.995–1)	0.099

Variables considered in the univariate analysis: type of catheter (ECC vs BCV) sex, gestational age at insertion, weight at insertion, cesarean delivery, CRIB score, 5 min Apgar score, respiratory distress syndrome (RDS), day of CVC insertion, parenteral nutrition days per CVC, antibiotics days per CVC, transfusion of packed red blood cells during CVC permanence, and CVC placement attempts (number of punctures). Only variables with a p value < 0.1 in the univariate analysis are shown. Only variables that remained significant in the multivariate analysis are shown

Discussion

CLABSI is a major complication during the maintenance of CVCs and has an adverse impact on morbidity/mortality, health care costs, and neurological long-term outcomes of preterm infants [15, 16]. The risk of CLABSI is greater in preterm infants than in older infants, children, and adults due to the unique vulnerability of immature infants, their prolonged CVC dwell times, and their high-intensity critical care needs [17]. Major efforts have been made to control risk factors and reduce the CLABSI-associated burden [18-20]. One aspect that might influence the CLABSI rate is the type of CVC and the insertion technique [1, 21]. In this observational study, we found a significantly lower rate of CLABSI when US-guided supraclavicular BCV catheters were used compared to standard ECCs in preterm infants. Importantly, such a difference has been observed despite BCV catheters being used in higher-risk infants and staying in place for a longer period [22]. Seemingly, the observed reduction in CLABSI was driven by a reduced incidence of CLABSI episodes caused by CoNS. While mortality of SCN sepsis is low, the detrimental effects on neurologic development are substantial and similar to those of more virulent bacteria [23, 24]. Therefore, we consider our finding of clinical relevance.

Some previous research has suggested that percutaneous CVCs are associated with an increased risk of infection compared to ECCs in children, though the results among studies are contradictory [25, 26]. In neonates, percutaneous CVCs are believed to carry a greater risk of CLABSI than ECCs, although supporting evidence is lacking [27]. Of note, no study has compared US-guided BCV cannulation with standard vascular access in preterm infants. One previous study by Habas et al. specifically assessed the risk of CLABSI with US-guided supraclavicular BCV cannulation against other CVC insertion sites (femoral, internal jugular vein, and infraclavicular subclavian vein) in older children in the pediatric intensive care unit (PICU), with the authors reporting a reduced CLABSI density rate (BCV, 2.8/1000 days vs other-CVC, 8.96/1000 days; p = 0.006) [28]. In a retrospective analysis, Biasucci D et al. observed a remarkable reduction in CLABSI from 15/1000 to 1.5/1000 days after the implementation of a CVC insertion bundle in the PICU [29]. The bundle included systematic assessment of central veins using the RaCeVa protocol and resulted in a radical shift in the choice of CVC insertion site in favor of the BCV (from 0 to 85% after bundle implementation) [30]. Other innovative elements in their bundle included routine tunneling of the catheter, sutureless fixation, glue sealing of the exit site, and specific simulation training; therefore, it is difficult to ascertain the exact contribution of BCV cannulation to the observed decrease in CLABSI.

The potential technical advantages of the US-guided supraclavicular approach for the BCV have been previously highlighted and include access to a large vein, fine control of needle advancement, a high first-pass cannulation success rate with few mechanical complications, and technical feasibility even in low-weight infants [31]. However, the reasons why this technique may reduce the risk of catheter colonization and infection are less obvious. Coagulation activation and the formation of a fibroblastic sleeve along the catheter interfere with biofilm formation, bacterial growth, and colonization of the extraluminal side of the catheter [32, 33]. Additionally, the high first-attempt insertion success rate achieved with the US-guided supraclavicular approach might lead to less endothelial damage during insertion and reduced thrombogenesis. In fact, in our study, the number of puncture attempts was an independent risk factor for CLABSI. Moreover, blood flow stasis is a classic pathogenic determinant of thrombus formation; in this sense, among the veins amenable to percutaneous catheterization, the BCV is the largest and has the highest flow, which permits a high catheter-to-vein diameter ratio without flow disruption [34-36]. Exit sites in the supraclavicular area may also contribute to reducing contamination and avoiding site humidity, which facilitates easier adhesion of dressings [37]. In contrast to ECC lines, a large-bore CVC facilitates repeated blood sampling, avoiding peripheral venipunctures during catheter use, a factor that has been implicated in bacteremia and catheter colonization during the use of ECCs [38].

ECCs are often inserted after the removal of UVCs. These devices permit infusion rates up to 1–2 ml/min, which are adequate for infusion of fluids, blood products, medications, or vasoactive drugs in most infants [39]. Nonetheless, ECCs do not permit the blood sampling, hemodynamic monitoring, multiple simultaneous infusions, or high-flow infusion rates that may be needed in critically ill preterm infants. Additionally, insertion failure rates are relatively high, and progression to a central position is hazardous even in experienced hands [40]. Catheter dysfunction and mechanical complications such as thrombosis and infiltration are relatively frequent, which often leads to nonelective removal [41].

If BCV cannulation is highly successful and catheter performance is superior to ECCs, why are percutaneous BCV catheters not inserted in most neonates who need central vein access when the umbilical vein is no longer available? We consider that there are some important limitations for the widespread use of BCV cannulation in preterm infants. The insertion of a percutaneous CVC through the BCV in a preterm is a challenging and delicate procedure. To be performed safely, it requires a deeply sedated and motionless infant, which is not always feasible. In addition, to be fully implemented, this approach would require around-the-clock availability of staff with sufficient expertise in US-guided cannulation. Finally, studies supporting BCV cannulation have been performed by highly experienced groups (pediatric anesthesiologists and vascular access teams) and have consisted of case series with near 100% insertion success rates but without any comparison to standard techniques; therefore, a publication bias may be a concern [4, 31]. However, if our findings are confirmed in other studies, reduced CLABSI should be taken into account together with already known technical advantages in the decision to insert BCV catheters in preterm infants, and the indication of this new vascular access might be expanded.

Our study has some limitations. This is a single-center nonrandomized retrospective study that included a limited number of preterm infants; accordingly, our results should be considered a proof of concept and taken with caution. As all observational studies, there is an inherent risk of confounding bias. We tried to reduce this risk by selecting matched controls. However, a more refined approach would have been to include all patients and perform propensity score matching [42]; in our infant population, BCV cannulation was performed in selected infants by a unique experienced intensivist, whereas ECCs were inserted by a team of 10 nurses who might have heterogeneous levels of expertise [43]. Regardless, all nurses were certified neonatal practitioners and used the same protocol for ECC insertion. Infants with BCV catheters received more days of antibiotic therapy during CVC use, which might have had a protective effect on CLABSI and act as a confounder. However, the antibiotic protocol was common and the difference in antibiotic days coverage was driven by differences in indwelling time without an observable effect of antibiotics on CLABSI rate in the multivariate analysis. In addition, the CVC maintenance policy was the same for both types of catheters. Finally, as BCV catheters were inserted in patients in poorer condition and the indwelling duration was longer than that of ECCs, we think that there was no significant risk of bias favoring BCV catheters. Some aspects of our CVC insertion and maintenance policy are controversial. We used surgical suture for fixation of BCV catheters. This should be avoided whenever possible given that it may increase the risk of infection. Commercially available sutureless devices are a better option. In the same line, the use of low-dose heparin to maintain catheter patency is outdated and not supported by current scientific evidence [44]. Finally, our ECC CLABSI rate is relatively high compared to those reported by studies from other countries. For these reasons, our results may lack external validity [12, 22].

Conclusions

US-guided supraclavicular cannulation of the BCV in our very-low-birth-weight preterm infants was associated with a reduced incidence of CLABSI compared to standard ECCs. This fact should be taken into account in selected infants who need a large-bore CVC and should prompt additional multicenter prospective studies on the subject.

What is Known: • An epicutaneous-cava catheter (ECC) is commonly used in preterm infants for routine care (eg. delivery of nutrition and antibiotics) but this device may not suffice in infants who need high-intensity care (multiple drugs, hemodynamic monitoring, fluid resuscitation etc.). • Ultrasound-guided brachiocephalic vein (BCV) catheterization has shown a high success rate and few immediate complications in neonates and small infants but it has never been compared to standard ECCs.

What is New: • When the operator in properly trained, US guided cannulation of the BCV in preterm infants is feasible, safe and may reduce the risk of CLABSI compared to standard ECCs. • This fact may expand the use of BCV catheters in selected high-risk preterm infants who need a large bore venous access.